Across life sciences organizations, data increases by the second, with much of it never reaching its full scientific or business value. Too often, critical data sits idle, collecting digital dust, reducing your agility, stifling productivity, and hindering your overall operational resilience. Every piece of data collected requires well-planned management for organization, storage, maintenance, and reuse in a manner that is reliable, preserves data integrity, and extends accessibility of the data.
Organizations must transform traditional ways of working to ensure the value of data extends far beyond its immediate analytical purpose to broader goals, such as leveraging analytical data to inform decisions through later clinical development, risk reduction, and predictive and strategic insight. This spans analytical, meta, instrument, column, and service data, and its governance. A key piece of this is taking practical steps to use FAIR data principles to ensure that your critical data is Findable, Accessible, Interoperable and Reusable – via secure, scalable platforms for downstream analysis – to help you create your resilient ecosystem.
Realistically, no organization can achieve true resilience or digital acceleration without well-designed, lifecycle-driven data management. And today’s laboratories cannot afford to treat data as an individualized, short-lived byproduct of analysis. Instead, data must become a durable, contextualized, governed asset that is ready to be reused, connected, and trusted across your enterprise. Analytics and AI will not happen effectively without this, and the laboratory of the future will not become reality without harnessing this power.
The hidden cost of “good enough” practices
Analytical laboratories already know where the hiccups and bottlenecks live. From inconsistencies, preventable errors, root-cause analysis, rework, and investigations to scattered data silos, inconsistent metadata, manual handoffs, weak traceability, and challenging review workflows, laboratory efficiency can end up in a constant fragile state. When data is captured without an intentional plan for mitigating risks, organization, storage, maintenance, reuse, and solid governance, systemic problems emerge:
Agility erodes. Each transfer, copy, or re-entry creates lag and increases risk. Investigations and method changes take longer. Scaling across sites and modalities becomes a time-consuming project, not a routine practice.
Operational resilience shrinks. Incomplete context (instrument state, chromatographic column history, comparative trends, data lineage) impairs root-cause analysis. A single out-of-trend event cascades into days of detective work.
Digital journeys dead-end. Analytics, AI, and ML are ineffective, expensive experiments without the critical foundation: quality data.
According to Gartner research from 2020, poor data quality costs organizations at least $12.9 million a year on average (1). To break the cycle, we need to treat every new data point as the start of a reusable, governed asset, not just evidence for a single point in time, pass/fail decision. And for maximized data usability, we also need to consider how we can leverage reliable and robust analytical tools and processes to build intrinsic quality into the data before the digital component even starts.
When data isn’t managed, risk multiplies
Data governance provides some level of assurance of data integrity (2). Data integrity issues rarely stem from a single point of failure. They accumulate gradually, and sometimes invisibly, through:
Inconsistent method performance and data
Incomplete metadata
Manual transcription and breaks in automation
Limited traceability
Undocumented column history
Pressures to pass data for timelines or metrics
Lapses in quality risk management, validation, instrument maintenance, and training
Sporadic review
Aging systems and technology
As issues compound, they erode operational resilience and work to make your quality systems more reactive than predictive. Documented risk assessments using ICH Q9(R1) principles (3) help you identify, think through, and mitigate the potential risks to your overall data integrity. This is a critical component of your data management.
If left unmitigated through design or operationalization, potential risks slow down your decision making, lengthen investigations, and reduce trust in the data needed for scientific, regulatory, and strategic insight. Without the fundamentals of data management in place, organizations simply cannot leverage data for advanced analytics, AI, and ML responsibly in a GxP context. There will be little confidence in reuse of the data for these advanced purposes, and in the application of the key guiding principles (4).
What a Resilient Analytical Data Ecosystem Requires
Integrated longitudinal data capture: Analytical results and metadata collected at different timepoints, from early-phase studies through to commercialization, captured, linked, and harmonized to provide a complete, traceable, and actionable dataset over the product lifecycle.
Consistent analytical data: Analytical methods developed and validated following ICH Q14 (5) and leveraging robust and reliable technologies to ensure accurate, precise, and high-quality data throughout development and commercialization.
Context at the point of data capture: Instrument state, method details, column identity, operator actions, and audit trails must be bound to the data instantly and automatically.
Consistent processing and review: Reduced risk to subjectivity, trained staff, and tools to simplify reviews.
Supported staff: Data literacy, qualifications, access to vendor expertise, and understanding of risks to patient safety, product quality, and decision making.
Immutable provenance: Full lineage from method creation through processing, revisions, and signoffs helps increase confidence not only in results, but in the decisions based upon them.
Vigilant monitoring: Structured risk analysis output and analytical procedure development with clear understanding of what requires monitoring.
Data reusability: Data created once should be ready to support everything from investigations to continuous verification, emergent trend identification, and AI model training.
Intrinsic compliance: Data integrity, as a foundation to compliance and product safety, inherent in business processes and computerized systems so it happens without conscious thought or action.
Building the next-generation laboratory
Effective analytical procedures, data management, and data governance work together with your overall quality system. They work together to open the door to data reuse, proactive monitoring, trending, and the ability to leverage your data for advanced analytics, AI, and ML. With these expanded capabilities, your data goes to work for you and becomes a key risk-reduction asset.
When organizations elevate analytical, meta, instrument, column, and service data to governed, reusable assets that move in downstream across the product lifecycle, three strategic benefits are achieved:
Risk reduction: Prevention with risk designed out of systems, processes, and workflows, and earlier detection when issues arise, for faster investigations that narrow windows of exposure.
Resilience: Well-understood and standardized operations, with early-phase data captured, linked, and contextualized to provide real-time insights, identification of emerging trends, and support for better-informed decisions throughout later phases of product development.
Velocity: Data becomes a platform for driving continuous improvement across all aspects of operations, breaking the traditional tradeoff between speed and quality.
Integrated, intelligent ecosystems that equip you with real-time monitoring, predictive risk management, and automated data interpretation are enabled by technology, alongside organizational and cultural shifts. For the next-generation laboratory, AI is no longer a distant concept. The possibilities of its use are reshaping the foundations of analytical science.
As organizations grapple with growing data complexity, regulatory scrutiny, and the demand for faster insights, AI offers you new pathways for potential innovation in key areas:
Data-informed decision making: Leveraging historical and early-phase data to optimize development, reduce variability, and guide trial design.
Method development: Speeding up optimization and reducing variability.
Workflow optimization: Intelligent scheduling and resource allocation.
Automated data interpretation: Reducing manual reviews and improving accuracy.
Decision support: Predictive analytics for faster, smarter decisions.
AI is poised to be a catalyst for resilience, efficiency, and scientific excellence in the next-generation laboratory, where intelligent systems reduce analyst burden, minimize errors, and make data integrity intrinsic by design, collectively accelerating your quality management maturity.
Resilience is a practice
In a world where science moves faster, regulatory scrutiny increases, and digital ambitions expand, laboratories cannot rely on fragmented data. The organizations that will thrive are those that treat data with the same intentionality they give analytical methods, materials, and instruments, ensuring it remains accessible, accurate, contextual, and trusted for years beyond its initial purpose. Putting data management to work for you now helps make your data AI-ready, whether AI is implemented today or three years from now.
We believe the most resilient laboratories are built not by adding complexity, but by strengthening the integrity and interconnectedness of the data that underpins every scientific decision. And that begins with reimagining how analytical data is captured, governed, and used, so it never becomes digital dust, but instead becomes a durable engine of your scientific and operational excellence.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
References
-
Gartner, “Data Quality: Best Practices for Accurate Insights.” Available at: https://www.gartner.com/en/data-analytics/topics/data-quality
- PIC/S, “Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments.” (2001). Available at: https://picscheme.org/docview/4234
- ICH, “Quality Risk Management Q9 (R1)” (2023). Available at: https://database.ich.org/sites/default/files/ICH_Q9(R1)_Guideline_Step4_2022_1219.pdf
- US FDA, “Guiding Principles of Good AI Practice in Drug Development” (2026). Available at: https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development
- ICH, “Analytical Procedure Development Q14,” (2022). Available at: https://database.ich.org/sites/default/files/ICH_Q14_Document_Step2_Guideline_2022_0324.pdf
